Latest Europe News

Amplia Therapeutics reports encouraging clinical progress for its pancreatic cancer drug narmafotinib, with a 35% confirmed response rate in the ACCENT trial and FDA support for dose optimisation. The company also uplisted to the US OTCQB market and secured a key patent extending protection to 2040.

Resmed Inc. posted robust Q2 FY2026 results, with revenue climbing 11% to $1.4 billion and a 16% rise in non-GAAP earnings per share, underpinned by strong global demand and operational efficiencies.

Titomic has made significant strides in transitioning from development to production, securing key contracts in defense and semiconductor sectors while maintaining a strong cash position.

Vanadium Resources Limited is advancing its Steelpoortdrift Vanadium Project with a new CEO and a sharpened focus on near-term cash flow and critical mineral markets in the US and EU.

Medical Developments International has posted positive operating cashflow for the first half of FY26, driven by robust growth in its flagship product Penthrox across Australia and Europe, alongside progress in paediatric approvals.

Little Green Pharma reports record quarterly revenue and announces a transformative merger with Cannatrek, creating a leading vertically integrated medicinal cannabis group with strong European growth prospects.

Aurora Labs has marked a significant milestone by securing its first purchase order for micro gas turbine engines, alongside strategic MOUs with major defence groups and a $5.5 million capital raise to fuel growth.

Argosy Minerals has made significant strides in developing its Rincon Lithium Project in Argentina, securing a crucial 40MW power connection and executing a lithium carbonate spot sales contract, all while navigating a buoyant lithium market.

European Metals Holdings has marked a pivotal quarter with the completion of a Definitive Feasibility Study for its Cinovec Lithium Project, securing a €360 million Czech government grant and submitting a key Environmental Impact Assessment, propelling the project closer to production.

Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.

ASF Group Limited closed December 2025 with $1.91 million in cash and nearly four quarters of funding runway, while progressing key investments in mining, technology, and biotech sectors.

Immutep Limited has entered a strategic collaboration with Dr. Reddy’s, receiving a A$30 million upfront payment and potential milestones up to A$528 million, while reporting promising clinical progress across multiple cancer immunotherapy trials.